COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP

Blood Adv. 2022 Apr 12;6(7):2427-2433. doi: 10.1182/bloodadvances.2021005616.


  1. The EHA-IDWP developed an observational registry collecting data on COVID-19 infection in patients who received CAR T-cell therapy.

  2. Prevalence of COVID-19 was 4.8%, and overall mortality was 50%, highlighting the need for prevention of infection in these patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19*
  • Humans
  • Immunotherapy, Adoptive
  • Receptors, Chimeric Antigen*
  • T-Lymphocytes


  • Receptors, Chimeric Antigen